{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[8,2,8,3],[9,2,9,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910830561803321"]
[null,null,"Titolo",null,"Disordered pharmaceutical materials / / edited by Marc Descamps"]
[null,null,"Pubbl/distr/stampa",null,"Weinheim, Germany : , : Wiley-VCH Verlag GmbH & Company KGaA, , [2016]"]
[{"$nulls":4},"©2016"]
[null,null,"ISBN",null,"3-527-65269-8"]
[{"$nulls":4},"3-527-65272-8"]
[{"$nulls":4},"3-527-65271-X"]
[{"$nulls":4},"9783527652693"]
[null,null,"Descrizione fisica",null,"1 online resource (646 p.)"]
[null,null,"Soggetti",null,"Materials biomèdics"]
[{"$nulls":4},"Biotecnologia farmacèutica"]
[{"$nulls":4},"Pharmaceutical biotechnology"]
[{"$nulls":4},"Biomedical materials"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Title Page; Copyright; Table of Contents; List of Contributors; Chapter 1: Some Facets of Molecular Disorder in Crystalline and Amorphous Pharmaceuticals; 1.1 The Crystal/Amorph Alternative; 1.2 Characteristics of the Disorder in Glass Formers; Acknowledgments; References; Chapter 2: Influence of Disorder on Dissolution; 2.1 Introduction; 2.2 Approaches to Enhance Solubility; 2.3 Measuring the Solubility Advantage of Amorphous Compounds; 2.4 Solid Dispersions; 2.5 Polymer Properties; 2.6 Drug-Polymer Interactions; 2.7 Polymer Concentration; 2.8 Other Formulation Components"]
[{"$nulls":4},"2.9 Formulation Variables2.10 Reliable Measurement of Supersaturation; 2.11 Conclusion; References; Chapter 3: Crystal Imperfections in Molecular Crystals: Physical and Chemical Consequences; 3.1 Introduction; 3.2 General Aspects of Defects in Crystals; 3.3 Role of Imperfections in Reactivity and Stability - Chemistry in the Perfect and Imperfect Lattice; 3.4 Role in Physical Processes; 3.5 Concluding Remarks; References; Chapter 4: Observation and Characterization of Crystal Defects in Pharmaceutical Solids; 4.1 Introduction; 4.2 Techniques for Characterizing Defects within Crystals"]
[{"$nulls":4},"4.3 Techniques for Characterizing Defects Emergent at Crystal Surfaces4.4 Techniques for Quantifying Defect Densities within Crystals; 4.5 The Complementarity of Techniques for Characterizing Defects; 4.6 Summary and Outlook; Acknowledgment; References; Chapter 5: \"Enantiomeric Disorder\" Pharmaceutically Oriented; 5.1 Introduction; 5.2 Introduction and Lexicon of Specific Terms Used among Chiral Molecules and Chiral Molecular Associations; 5.3 Restrictions in Symmetry Operations Inside Crystal Lattices with an Enantiomeric Excess Different from Zero"]
[{"$nulls":4},"5.4 Impact of Chirality on Phase Diagrams and the Gibbs-Scott Phase Rule5.5 Competitions between Solid Solutions (Impact of Polymorphism on Solid Solutions) Application: Preferential Enrichment; 5.6 Disorder at Level 3 Multiepitaxy between Enantiomers; 5.7 Conclusion and Perspectives; Acknowledgments; References; Chapter 6: Conformational Disorder and Atropisomerism in Pharmaceutical Compounds; 6.1 Premise: Conformational Energy Barriers in Flexible Molecules; 6.2 Conformational Topology and Crystallization of Chain Molecules"]
[{"$nulls":4},"6.3 Conformational Polymorphism and Crystallization of Flexible Molecules6.4 Conformational Flexibility of Ring Molecules: Carbohydrates; 6.5 Hindered Conformational Isomerism: Atropisomerism; 6.6 Conclusion; Acknowledgments; References; Chapter 7: Tautomerism in Drug Delivery; 7.1 Broadband Dielectric Spectroscopy as a Powerful Tool for Investigating the Tautomerization Process in Condensed Materials; 7.2 Tautomerization Kinetics of Supercooled Pharmaceuticals; Acknowledgment; References; Chapter 8: Disorders in Pharmaceutical Polymers; 8.1 Polymers Architectures - Structural Disorders"]
[{"$nulls":4},"8.2 Structural States and Phases Transitions"]